Moderna: 85% fall in Q4 EPS

(CercleFinance.com) - Moderna has reported EPS of 55 cents for the last three months of 2023, compared with $3.
61 a year earlier, reflecting a 45% fall in revenues to $2.8bn, linked to reduced sales of Covid-19 vaccines. NB pmt +5.6%

2023 has been a year of transition for Moderna, acknowledged CEO Stéphane Bancel, who nevertheless pointed to significant progress made by the biotech group in infectious diseases, oncology and rare diseases.

Moderna reiterates its forecast for product sales of around four billion dollars in 2024, and expects regulatory approvals for its RSV vaccine for the elderly to begin in H1 this year.


Copyright (c) 2024 CercleFinance.com. All rights reserved.